Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report
ConclusionsThis is the first study to present pralatrexate as a successful bridge to allogeneic hematopoietic stem cell transplantation in a 29-year-old Asian male patient with advanced-stage extranodal natural killer/T cell lymphoma refractory to first-line dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy. This case provides a novel treatment opinion for extranodal natural killer/T cell lymphoma, esp ecially for the Far East Asian population.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Dexamethasone | General Medicine | Lymphoma | Methotrexate | Nasal Cavity and Paranasal Sinus Cancer | Skin | Stem Cell Therapy | Stem Cells | Study | T-cell Lymphoma | Transplants